Core Concepts
Specific scleroderma autoantibodies can predict cancer risk in patients.
Stats
A total of 676 patients with scleroderma and a history of cancer were compared with 687 control patients with scleroderma but without a history of cancer.
Anti-POLR3 and monospecific anti-Ro52 were associated with significantly increased overall cancer risk.
Anti-centromere and anti-U1RNP were associated with a decreased cancer risk.
Patients positive for anti-Ro52 in combination with either anti-U1RNP or anti-Th/To had a decreased risk of cancer.
Quotes
"Anti-POLR3 and monospecific anti-Ro52 were associated with significantly increased overall cancer risk."
"Patients positive for anti-Ro52 in combination with either anti-U1RNP or anti-Th/To had a decreased risk of cancer."